Retour

Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15

Calendar Calendar of Events

LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day.

GlobeNewswire Inc. • 09/05/2024 à 13:00:00
Renalytix plc American Depositary Shares
Address: FINSGATE
Postal Code: EC1V 9EE
City: LONDON
State: X0
Phone Number: 44 29 2071 0570
Website: https://www.renalytix.com
Status: Active
Company Info

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

List Date2020-07-17
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeADRC
Currency NameUSD
CIK0001811115
Composite figiBBG00VPNC562
Share Class figiBBG00VPNC5Z0
Market Cap37,850,972 USD
SIC Code8071
SIC DescriptionSERVICES-MEDICAL LABORATORIES
Total Employees110
Share Class Shares Outstanding154370000
Weighted Shares Outstanding73769191
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
18-05
17-05
16-05
15-05
14-05
Last
0.512
0.511
0.589
0.58
0.67
Variance
0%
-13.24%
1.55%
-12.78%
8.24%
Open
0.512
0.589
0.58
0.665
0.619
Highest
0.512
0.589
0.596
0.685
0.67
Lowest
0.512
0.589
0.595
0.685
0.67
History
PeriodVarhighestlowest
1 week
-17.01%
0.623
0.512
1 month
-34.56%
0.811
0.512
3 month
-37.18%
0.828
0.512
6 month
-7.68%
0.5925
0.2449
1 year
-75.02%
2.2464
0.2449
3 year
-98.36%
33
0.2449
5 year
-96.28%
14.74
0.2449
10 year
-96.28%
14.74
0.2449
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-11-14 UNPUB UNPUB UNPUB
Assets 19,540,000 UNPUB UNPUB UNPUB
Current Assets 16,471,000 UNPUB UNPUB UNPUB
Current Liabilities 15,173,000 UNPUB UNPUB UNPUB
Equity -1,491,000 UNPUB UNPUB UNPUB
Equity Attributable To Noncontrolling Interest 0 UNPUB UNPUB UNPUB
Equity Attributable To Parent -1,491,000 UNPUB UNPUB UNPUB
Liabilities 21,031,000 UNPUB UNPUB UNPUB
Liabilities And Equity 19,540,000 UNPUB UNPUB UNPUB
Noncurrent Assets 3,069,000 UNPUB UNPUB UNPUB
Noncurrent Liabilities 5,858,000 UNPUB UNPUB UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-11-14 UNPUB UNPUB UNPUB
Exchange Gains/Losses -222,000 UNPUB UNPUB UNPUB
Net Cash Flow 222,000 UNPUB UNPUB UNPUB
Net Cash Flow, Continuing 444,000 UNPUB UNPUB UNPUB
Net Cash Flow From Financing Activities -1,065,000 UNPUB UNPUB UNPUB
Net Cash Flow From Financing Activities, Continuing -1,065,000 UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities 10,791,000 UNPUB UNPUB UNPUB
Net Cash Flow From Investing Activities, Continuing 10,569,000 UNPUB UNPUB UNPUB
Net Cash Flow From Operating Activities -9,504,000 UNPUB UNPUB UNPUB
Net Cash Flow From Operating Activities, Continuing -9,504,000 UNPUB UNPUB UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-11-14 UNPUB UNPUB UNPUB
Comprehensive Income/Loss UNPUB UNPUB UNPUB UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 10,037,000 UNPUB UNPUB UNPUB
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Other Comprehensive Income/Loss UNPUB UNPUB UNPUB UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-11-14 UNPUB UNPUB UNPUB
Basic Earnings Per Share 0 UNPUB UNPUB UNPUB
Benefits Costs and Expenses 10,613,000 UNPUB UNPUB UNPUB
Cost Of Revenue 502,000 UNPUB UNPUB UNPUB
Costs And Expenses 10,613,000 UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 UNPUB UNPUB UNPUB
Gross Profit -43,000 UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -10,154,000 UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations Before Tax -10,154,000 UNPUB UNPUB UNPUB
Income Tax Expense/Benefit 0 UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -10,154,000 UNPUB UNPUB UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 UNPUB UNPUB UNPUB
Net Income/Loss Attributable To Parent -10,154,000 UNPUB UNPUB UNPUB
Net Income/Loss Available To Common Stockholders, Basic -10,154,000 UNPUB UNPUB UNPUB
Operating Expenses 8,846,000 UNPUB UNPUB UNPUB
Operating Income/Loss -8,889,000 UNPUB UNPUB UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 UNPUB UNPUB UNPUB
Preferred Stock Dividends And Other Adjustments 0 UNPUB UNPUB UNPUB
Revenues 459,000 UNPUB UNPUB UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2023-09-28
Assets UNPUB UNPUB UNPUB 30,629,000
Current Assets UNPUB UNPUB UNPUB 26,882,000
Current Liabilities UNPUB UNPUB UNPUB 16,136,000
Equity UNPUB UNPUB UNPUB 6,967,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Equity Attributable To Parent UNPUB UNPUB UNPUB 6,967,000
Liabilities UNPUB UNPUB UNPUB 23,662,000
Liabilities And Equity UNPUB UNPUB UNPUB 30,629,000
Noncurrent Assets UNPUB UNPUB UNPUB 3,747,000
Noncurrent Liabilities UNPUB UNPUB UNPUB 7,526,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2023-09-28
Exchange Gains/Losses UNPUB UNPUB UNPUB 1,048,000
Net Cash Flow UNPUB UNPUB UNPUB -1,048,000
Net Cash Flow, Continuing UNPUB UNPUB UNPUB -2,096,000
Net Cash Flow From Financing Activities UNPUB UNPUB UNPUB 16,386,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB UNPUB 16,386,000
Net Cash Flow From Investing Activities UNPUB UNPUB UNPUB 16,651,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB UNPUB 17,699,000
Net Cash Flow From Operating Activities UNPUB UNPUB UNPUB -34,085,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB UNPUB -34,085,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2023-09-28
Comprehensive Income/Loss UNPUB UNPUB UNPUB UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 46,142,000
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Other Comprehensive Income/Loss UNPUB UNPUB UNPUB UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB UNPUB 2023-09-28
Basic Earnings Per Share UNPUB UNPUB UNPUB -1
Benefits Costs and Expenses UNPUB UNPUB UNPUB 49,008,000
Cost Of Revenue UNPUB UNPUB UNPUB 2,683,000
Costs And Expenses UNPUB UNPUB UNPUB 49,008,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB -1
Gross Profit UNPUB UNPUB UNPUB 720,000
Income/Loss From Continuing Operations After Tax UNPUB UNPUB UNPUB -45,607,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB UNPUB -45,605,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 2,000
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB UNPUB -45,607,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB UNPUB 0
Net Income/Loss Attributable To Parent UNPUB UNPUB UNPUB -45,607,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB UNPUB -45,607,000
Operating Expenses UNPUB UNPUB UNPUB 42,941,000
Operating Income/Loss UNPUB UNPUB UNPUB -42,221,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB UNPUB 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB UNPUB 0
Revenues UNPUB UNPUB UNPUB 3,403,000
Calendar
20 May 2024 (Time UTC) Actual Previous Consensus
★★
09:00
United States
★★
09:00
United States
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-5400.000
-17800.000
★
15:30
United States
-66000.000
-60000.000
★
15:30
United States
59500.000
53700.000
★
15:30
United States
-116600.000
-135800.000
★★
15:30
United States
3200.000
4400.000
★
15:30
United States
203000.000
215400.000
★
15:30
United States
200.000
-31400.000
★
15:30
United States
61800.000
62600.000
★
15:30
United States
1300.000
1300.000
★
15:30
United States
-25300.000
-9700.000
★
15:30
United States
204500.000
199600.000
★★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:RNLX240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:RNLX240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:RNLX240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:RNLX240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:RNLX240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:RNLX240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:RNLX240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:RNLX240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:RNLX240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:RNLX240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:RNLX240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:RNLX240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:RNLX240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:RNLX240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:RNLX240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:RNLX240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:RNLX240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:RNLX240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:RNLX240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:RNLX240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:RNLX240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:RNLX240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:RNLX240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:RNLX240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:RNLX240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:RNLX240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:RNLX240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:RNLX240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:RNLX240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:RNLX240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:RNLX231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:RNLX231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:RNLX231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:RNLX231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:RNLX231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:RNLX231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:RNLX231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:RNLX231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:RNLX231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:RNLX231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:RNLX231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:RNLX231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:RNLX231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:RNLX231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:RNLX231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:RNLX231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:RNLX231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:RNLX231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:RNLX230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:RNLX230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:RNLX230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:RNLX230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:RNLX230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:RNLX230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:RNLX230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:RNLX230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:RNLX230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:RNLX230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:RNLX230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:RNLX230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Stocks Earnings Releases and Operating Results
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024.
GlobeNewswire Inc. • 4d ago
Calendar Calendar of Events
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day.
GlobeNewswire Inc. • 1w ago
Stocks Financing Agreements
Renalytix Announces Financing with Expected Size of up to $4 Million
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per NASDAQ ADS ($0.375 per common stock share) (£0.0025 each) (the “Ordinary Shares”) (the “Fundraise”) to DB Capital Partners Healthcare, L.P. (the “Purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseases care. The Fundraise was conducted by way of a securities purchase agreement between the Purchaser and the Company which consists of an initial tranche of 2,666,667 Ordinary Shares initially for an amount of $1.0 million (the “Initial Tranche Shares”) with an optional subsequent tranche of Ordinary Shares at the option of the Purchaser. Both tranches are priced at $0.75 per NASDAQ ADS ($0.375 per Ordinary Share). The aggregate total amount for both tranches, if the option is fully exercised, is expected to be up to $4 million in total financing. The net proceeds of the Fundraise will be used to support commercial sales activity as the Company continues its Formal Sale Process, as previously announced.
GlobeNewswire Inc. • 1mo ago
Health Health
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
GlobeNewswire Inc. • 2mo ago
Health Health
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended December 31, 2023. The Company plans to issue another announcement following today’s report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events.
GlobeNewswire Inc. • 3mo ago
Calendar Calendar of Events
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.
GlobeNewswire Inc. • 3mo ago
Health Health
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months
GlobeNewswire Inc. • 4mo ago
Stocks Earnings Releases and Operating Results
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2023.
GlobeNewswire Inc. • 6mo ago
Calendar Calendar of Events
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
GlobeNewswire Inc. • 6mo ago
News News
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock
Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • 7mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT